 |
|
|
| |
Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
E.J. Gane1, C. Schwabe2, K. Walker2, L. Flores3, G.D. Hartman3, K. Klumpp3, S. Liaw3 and N.A. Brown3
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Clinical Trials Unit, Auckland Clinical Studies,
Auckland, New Zealand; 3Novira Therapeutics, Inc., Doylestown, PA , U.S.A.
|
| |
|
|
|
|
|
